AstraZeneca PLC (AZN) Advances PARP Inhibitor Into Phase 3 Trial With BRACAnalysis®
6/3/2013 10:22:15 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SALT LAKE CITY, June 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that AstraZeneca will use Myriad's BRACAnalysis test as a companion diagnostic to stratify patients in AstraZeneca's pivotal Phase 3 clinical studies for olaparib. Myriad has submitted an Investigational Device Exemption (IDE) with the U.S. Food and Drug Administration (FDA) for BRACAnalysis testing, which will allow the test to be used as a companion diagnostic to identify potential responders to olaparib therapy in the United States.
Help employers find you! Check out all the jobs and post your resume.
comments powered by